Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA - 05/11/16
, Giorgio Carlino b, Antonio Marchesoni c, Piercarlo Sarzi-Puttini d, Roberto Gorla e, Giovanni Lapadula aon behalf of GISEA (Gruppo Italiano di Studio sulle Early Arthritides)
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 5 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objectives |
The aim of this study was to assess whether good EULAR response assessed at 3months may predict the achievement of low disease activity (LDA) at 1year in rheumatoid arthritis (RA) patients on treatment with certolizumab pegol (CZP).
Methods |
From the nationwide Italian registry, we analysed 278 RA patients (age 54.8±12years, duration of disease 9.8±8years, female 84%) initiating CZP as first line (68%) or≥second line (32%) of biological treatment because of their active disease. Assessment of disease activity was based on 28 joint Disease Activity Score (DAS28). A reduction of DAS28>1.2 (good EULAR response) was assessed at 3months, and the achievement of LDA (DAS28≤3.2) was evaluated at 1year. Multiple regression models were used to estimate predictors of early good EULAR response or LDA.
Results |
The percentages of patients attaining good EULAR response were 52% at 3, 65% at 6, and 66% at 12months. Furthermore, 51.2% (98/192) of the patients reached LDA at 12months. Patients taking CZP as first biological treatment had adjusted odds ratios (OR) of good EULAR response at 3months 6 folds higher than in those with≥1 prior biological drug (OR 6.7, 95% CI 1.97–23.1). While, the strongest variable correlating with 12months LDA was the achievement of good EULAR response at 3months (OR 11.3, 95% CI 13.1–34.8).
Conclusions |
Our findings showed that attaining good EULAR response at 3months strongly predicted 1year LDA in RA patients treated with CZP in real-life settings.
Le texte complet de cet article est disponible en PDF.Keywords : EULAR response, GISEA, Registry, Anti-TNF
Plan
Vol 83 - N° 6
P. 721-725 - décembre 2016 Retour au numéro
Article précédent
- Diagnostic contribution of a second percutaneous needle biopsy in patients with spontaneous diskitis and negative blood cultures and first biopsy
- William Terreaux, Marion Geoffroy, Xavier Ohl, Louis Job, Philippe Cart, Jean-Paul Eschard, Jean-Hugues Salmon
- Pyogenic vertebral osteomyelitis caused by Yersinia pseudotuberculosis
- Toshinobu Ishihara, Masashi Miyazaki, Toyomi Yoshiiwa, Naoki Notani, Hiroshi Tsumura
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?